Firm Investigates Zimmer Biomet Holdings
The national shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH). The probe follows a 15% drop in the company's stock price and reduced revenue guidance, scrutinizing alleged failures in emerging markets and what the firm calls "inconsistent" execution.
- The investigation follows Zimmer Biomet's November 5, 2025, announcement of disappointing third-quarter financial results, which included last-minute distributor order cancellations in the Middle East and Eastern Europe. - On the same announcement, the company revealed it had significantly missed its sales forecast in Latin America by more than 15%. - These results contradicted the "very high" confidence in second-half revenue growth expressed by CEO Ivan Tornos during the August 7, 2025, second-quarter earnings call. - The unexpected weaknesses in these emerging markets, along with issues in the company's restorative therapies business, negatively impacted the company's growth by 120 basis points. - In response to the performance issues, Zimmer Biomet announced it is making "leadership and governance changes in some of our international businesses." - Following the November 5 announcement, the company's stock price fell by 15%, and Q3 revenue of $2 billion came in $10 million below analysts' expectations. - As a result of these challenges, Zimmer Biomet lowered its full-year 2025 organic constant currency revenue growth forecast to a range of 3.5% to 4%, down from the previous 3.5% to 4.5%. - In a subsequent earnings call, CEO Ivan Tornos acknowledged the need to be "far more measured" in the company's external commentary.
